image: Recognized for the impact on the future of drug discovery and development at the Fifth Endeavor Venture Group & Mount Sinai Health System Healthcare AI and Technology Investor Summit.
Credit: Endeavor Venture Group & Mount Sinai Health System Healthcare AI and Technology Investor Summit
Insilico Medicine (“Insilico”), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, is proud to be recognized for the impact on the future of drug discovery and development, as a distinguished honoree of the Showcase AI and Biotech Innovation Award on November 13, 2024, at the Fifth Endeavor Venture Group & Mount Sinai Health System Healthcare AI and Technology Investor Summit. Michelle Chen, Ph.D., Chief Business Officer of Insilico Medicine, received the award on behalf of the company.
Delivered with the joint efforts of Endeavor Venture Group and Mount Sinai Health system, the hybrid event gathered seasoned venture capitalists and over 175 health tech companies including Google, IBM, Northwell Health and Bayer, focusing on integrating cutting-edge technologies into hospitals, biopharma, and enterprises.
In 2016, Insilico first described the concept of using generative AI for the design of novel molecules in a peer-reviewed journal, which laid the foundation for the commercially available Pharma.AI platform. Since then, Insilico keeps integrating technical breakthroughs into Pharma.AI platform, which is currently a generative AI-powered solution spanning across biology, chemistry, medicine development and science research. Powered by Pharma.AI, Insilico has nominated 20 preclinical candidates in its comprehensive portfolio of over 30 assets since 2021 and has received IND clearance for 10 molecules.
In early 2024, Insilico published a Nature Biotechnology paper presenting the entire R&D journey from AI algorithms to Phase II clinical trials of ISM001-055, the company's lead drug pipeline with AI-discovered target and AI-designed structure. Following that, Insilico has recently announced positive preliminary results from a Phase IIa trial (NCT05938920), where ISM001-055 showed favorable safety and tolerability across all dose levels, as well as dose-dependent response in forced vital capacity (FVC), after only 12 weeks of dosage.
About Insilico Medicine
Insilico Medicine, a global clinical stage biotechnology company powered by generative AI, is connecting biology, chemistry and clinical trials analysis using next-generation AI systems. The company has developed AI platforms that utilize deep generative models, reinforcement learning, transformers and other modern machine learning techniques for novel target discovery and the generation of novel molecular structures with desired properties. Insilico Medicine is developing breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, immunity, central nervous system diseases, infectious diseases, autoimmune diseases, and aging-related diseases.